Article Data

  • Views 1983
  • Dowloads 221

Original Research

Open Access

Oral vs. IV paracetamol for pain control in patients with femur fracture in the emergency department: a practical randomized controlled trial

  • Francesco Franceschi1
  • Angela Saviano1,*,
  • Marcello Covino1
  • Marcello Candelli1
  • Veronica Ojetti1
  • Sara Cicchinelli1
  • Martina Petrucci1
  • Francesco Sardeo1
  • Enrico Torelli1
  • Rebecca Nicolò1
  • Evelina Forte1
  • Giulio Maccauro2

1Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy

2Orthopaedics and Traumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy

DOI: 10.22514/sv.2023.052 Vol.19,Issue 4,July 2023 pp.72-78

Submitted: 26 May 2022 Accepted: 03 August 2022

Published: 08 July 2023

*Corresponding Author(s): Angela Saviano E-mail: saviange@libero.it; angela.saviano@policlinicogemelli.it

Abstract

Femur fracture (FF) is a common reason for admission to the Emergency Department (ED) and pain is a frequent symptom. Effective and timely pain control is essential for these patients, however, the most appropriate analgesic therapy for quick pain relief in the ED setting is not well established. This is a single-center pragmatic randomized controlled study. We have enrolled 171 consecutive patients with FF and severe pain. They were randomized 1:5 to receive treatment with paracetamol 1000 mg orally (OR) or with paracetamol 1000 mg intravenously (IV). The effect on pain relief was measured with the Visual Analogue Scale for Pain (VAS) at baseline (T0), after 1 hour (T1), 2 hours (T2), and 4 hours (T4). The primary endpoint was the reduction of pain of 1 point of the VAS at T1. This target was reached by 75% of patients treated with paracetamol IV and 44% treated with paracetamol OR (p = 0.001). The secondary endpoint was the reduction of pain of at least 2 points of the VAS at T4, the need for rescue therapy, and the number of adverse events. At T4 the efficacy of paracetamol IV and OR resulted in 89.5% and 88.9%, respectively (p = 0.914). The 17.5% of patients treated with paracetamol IV vs. the 3.7% treated with paracetamol OR required rescue therapy (p = 0.082), with prevalence among women (p = 0.057). No adverse effects were reported. The treatment with paracetamol 1000 mg IV and OR resulted effective and safe for patients with FF waiting for surgery. IV administration was faster in reducing pain in the first 2 hours compared to oral administration but the latter required less rescue therapy. Interestingly, our study highlighted gender differences in pain relief opening the way for a gender-tailored therapy.


Keywords

Femur fracture; Pain; Paracetamol; Emergency department; Elderly


Cite and Share

Francesco Franceschi,Angela Saviano,Marcello Covino,Marcello Candelli,Veronica Ojetti,Sara Cicchinelli,Martina Petrucci,Francesco Sardeo,Enrico Torelli,Rebecca Nicolò,Evelina Forte,Giulio Maccauro. Oral vs. IV paracetamol for pain control in patients with femur fracture in the emergency department: a practical randomized controlled trial. Signa Vitae. 2023. 19(4);72-78.

References

[1] Dizdarevic A, Farah F, Ding J, Shah S, Bryan A, Kahn M, et al. A comprehensive review of analgesia and pain modalities in hip fracture pathogenesis. Current Pain and Headache Reports. 2019; 23: 72.

[2] Elsoe R, Ceccotti AA, Larsen P. Population-based epidemiology and incidence of distal femur fractures. International Orthopaedics. 2018; 42: 191–196.

[3] Bonnin MP, Neto CC, Aitsiselmi T, Murphy CG, Bossard N, Roche S. Increased incidence of femoral fractures in small femurs and women undergoing uncemented total hip arthroplasty—why? The Bone & Joint Journal. 2015; 97-B: 741–748.

[4] Mattisson L, Bojan A, Enocson A. Epidemiology, treatment and mortality of trochanteric and subtrochanteric hip fractures: data from the Swedish fracture register. BMC Musculoskeletal Disorders. 2018; 19: 369.

[5] Lim SJ, Yeo I, Yoon PW, Yoo JJ, Rhyu KH, Han SB, et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. Osteoporosis International. 2018; 29: 2427–2435.

[6] Roder F. Proximal femur fracture in older patients—rehabilitation and clinical outcome. Age and Ageing. 2003; 32: 74–80.

[7] Larsen P, Ceccotti AA, Elsoe R. High mortality following distal femur fractures: a cohort study including three hundred and two distal femur fractures. International Orthopaedics. 2020; 44: 173–177.

[8] Rowlands M, Walt GVD, Bradley J, Mannings A, Armstrong S, Bedforth N, et al. Femoral nerve block intervention in neck of femur fracture (FINOF): a randomised controlled trial. BMJ Open. 2018; 8: e019650.

[9] Uysal Aİ, Altıparmak B, Yaşar E, Turan M, Canbek U, Yılmaz N, et al. The effects of early femoral nerve block intervention on preoperative pain management and incidence of postoperative delirium geriatric patients undergoing trochanteric femur fracture surgery: A randomized controlled trial. Ulus Travma Acil Cerrahi Derg. 2020; 26: 109–114.

[10] Gangavalli AK, Nwachuku CO. Management of distal femur fractures in adults. Orthopedic Clinics of North America. 2016; 47: 85–96.

[11] Oc Y, Varol A, Yazar EA, Ak S, Akpolat AO, Kilinc BE. Treatment strategy for elderly patients with the isolated greater trochanteric fracture. SAGE Open Medicine. 2020; 8: 205031212096413.

[12] Li L, Bennett-Brown K, Morgan C, Dattani R. Hip fractures. British Journal of Hospital Medicine. 2020; 81: 1–10.

[13] Fabi DW. Multimodal analgesia in the hip fracture patient. Journal of Orthopaedic Trauma. 2016; 30: S6–S11.

[14] Kuberan A, Makkar J, Jain K, Balasubramanian M, Bhatia N, Singh P. Pre-emptive multimodal analgesic regimen reduces post-operative epidural demand boluses in traumatic shaft of femur fracture—a randomised controlled trial. Indian Journal of Anaesthesia. 2019; 63: 895.

[15] Soffin EM, Gibbons MM, Wick EC, Kates SL, Cannesson M, Scott MJ, et al. Evidence review conducted for the agency for healthcare research and quality safety program for improving surgical care and recovery. Anesthesia & Analgesia. 2019; 128: 1107–1117.

[16] Chuang P, Shen S, Yang T, Huang T, Huang K. Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study. BMC Musculoskeletal Disorders. 2016; 17: 201.

[17] Glinkowski W, Narloch J, Krasuski K, Śliwczyński A. The increase of osteoporotic hip fractures and associated one-year mortality in Poland: 2008–2015. Journal of Clinical Medicine. 2019; 8: 1487.

[18] Dixon J, Ashton F, Baker P, Charlton K, Bates C, Eardley W. Assessment and early management of pain in hip fractures: the impact of paracetamol. Geriatric Orthopaedic Surgery & Rehabilitation. 2018; 9: 215145931880644.

[19] Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care & Research. 2011; 63: S240–S252.

[20] Franceschi F, Marsiliani D, Alesi A, Mancini MG, Ojetti V, Candelli M, et al. A simplified way for the urgent treatment of somatic pain in patients admitted to the emergency room: the SUPER algorithm. Internal and Emergency Medicine. 2015; 10: 985–992.

[21] Di Filippo A, Magherini M, Ruggiano P, Ciardullo A, Falsini S. Postoperative analgesia in patients older than 75 years undergoing intervention for per-trochanteric hip fracture: a single centre retrospective cohort study. Aging Clinical and Experimental Research. 2015; 27: 281–285.

[22] Aprato A, Bechis M, Buzzone M, Bistolfi A, Daghino W, Massè A. No rest for elderly femur fracture patients: early surgery and early ambulation decrease mortality. Journal of Orthopaedics and Traumatology. 2020; 21: 12.

[23] Mubark I, Abouelela A, Genena A, Al Ghunimat A, Sarhan I, Ashwood N. Mortality following distal femur fractures versus proximal femur fractures in elderly population: the impact of best practice tariff. Cureus. 2020; 12: e10744.

[24] Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis International. 2012; 23: 2239–2256.

[25] Piscitelli P, Neglia C, Feola M, Rizzo E, Argentiero A, Ascolese M, et al. Updated incidence and costs of hip fractures in elderly Italian population. Aging Clinical and Experimental Research. 2020; 32: 2587–2593.

[26] Peeters CMM, Visser E, Van de Ree CLP, Gosens T, Den Oudsten BL, De Vries J. Quality of life after hip fracture in the elderly: a systematic literature review. Injury. 2016; 47: 1369–1382.

[27] Guzon-Illescas O, Perez Fernandez E, Crespí Villarias N, Quirós Donate FJ, Peña M, Alonso-Blas C, et al. Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. Journal of Orthopaedic Surgery and Research. 2019; 14: 203.

[28] Mian P, Allegaert K, Spriet I, Tibboel D, Petrovic M. Paracetamol in older people: towards evidence-based dosing? Drugs & Aging. 2018; 35: 603–624.

[29] Gazelka HM, Leal JC, Lapid MI, Rummans TA. Opioids in older adults: indications, prescribing, complications, and alternative therapies for primary care. Mayo Clinic Proceedings. 2020; 95: 793–800.

[30] Gemmati D, Varani K, Bramanti B, Piva R, Bonaccorsi G, Trentini A, et al. “Bridging the gap” everything that could have been avoided if we had applied gender medicine, pharmacogenetics and personalized medicine in the gender-omics and sex-omics era. International Journal of Molecular Sciences. 2019; 21: 296.

[31] Di Sanzo M, Cipolloni L, Borro M, La Russa R, Santurro A, Scopetti M, et al. Clinical applications of personalized medicine: a new paradigm and challenge. Current Pharmaceutical Biotechnology. 2017; 18: 194–203.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top